Selected article for: "cross reactivity and epitope specificity"

Author: Chaudhury, S.; Hutter, J. N.; Bolton, J. S.; Hakre, S.; Mose, E.; Wooten, A. I.; O'Connell, W. D.; Hudak, J.; Krebs, S. J.; Darden, J.; Regules, J. A.; Murray, C. K.; Mojarrad, K.; Peel, S. A.; Bergmann-Leitner, E. S.
Title: Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform
  • Cord-id: nnvi3cx9
  • Document date: 2021_3_26
  • ID: nnvi3cx9
    Snippet: Serological assessment of SARS-CoV-2 specific responses are an essential tool for determining the prevalence of past SARS-CoV-2 infections in the population especially when testing occurs after symptoms have developed and limited contact tracing is in place. The goal of our study was to test a new 10-plex electro-chemiluminescence-based assay to measure IgM and IgG responses to the spike proteins from multiple human coronaviruses including SARS-CoV-2, assess the epitope specificity of the SARS-C
    Document: Serological assessment of SARS-CoV-2 specific responses are an essential tool for determining the prevalence of past SARS-CoV-2 infections in the population especially when testing occurs after symptoms have developed and limited contact tracing is in place. The goal of our study was to test a new 10-plex electro-chemiluminescence-based assay to measure IgM and IgG responses to the spike proteins from multiple human coronaviruses including SARS-CoV-2, assess the epitope specificity of the SARS-CoV-2 antibody response against full-length spike protein, receptor-binding domain and N-terminal domain of the spike protein, and the nucleocapsid protein. We carried out the assay on samples collected from three sample groups: subjects diagnosed with COVID-19 from the U.S. Army hospital at Camp Humphreys in Pyeongtaek, South Korea; healthcare administrators from the same hospital but with no reported diagnosis of COVID-19; and pre-pandemic samples. We found that the new CoV-specific multiplex assay was highly sensitive allowing plasma samples to be diluted 1:30,000 with a robust signal. The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples. The data from the three sample groups also revealed a unique pattern of cross-reactivity between SARS-CoV-2 and SARS-CoV-1, MERS-CoV, and seasonal coronaviruses HKU1 and OC43. Our findings show that the CoV-2 IgM response is highly specific while the CoV-2 IgG response is more cross-reactive across a range of human CoVs and also showed that IgM and IgG responses show distinct patterns of epitope specificity. In summary, this multiplex assay was able to distinguish samples by COVID-19 status and characterize distinct trends in terms of cross-reactivity and fine-specificity in antibody responses, underscoring its potential value in diagnostic or serosurveillance efforts.

    Search related documents:
    Co phrase search for related documents
    • acute response and long period: 1
    • acute response and longitudinal study: 1, 2, 3, 4, 5, 6
    • acute response and low prevalence: 1, 2, 3
    • additional challenge and long term memory: 1
    • local outbreak and long period: 1
    • local outbreak and low disease: 1, 2, 3
    • local outbreak and low prevalence: 1
    • long period and low disease: 1, 2
    • long period and low prevalence: 1, 2, 3
    • long term memory and low variability: 1
    • longitudinal study and low disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • longitudinal study and low disease severity: 1
    • longitudinal study and low prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • low variability and machine learn: 1